WhiteOak Capital Pharma and Healthcare Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 20-12-2024
₹ 13.57
▲0.6%
1D
Inception Returns
36.9%
/yr
About WhiteOak Capital Pharma and Healthcare Fund Direct Growth
WhiteOak Capital Pharma and Healthcare Fund Direct Growth is an equity fund. This fund was started on 6 February, 2024. The fund is managed by Piyush Baranwal. The fund could potentially beat inflation in the long-run.
Key Parameters
- WhiteOak Capital Pharma and Healthcare Fund Direct Growth has ₹254 Cr worth of assets under management (AUM) as on Nov 2024 and is less than category average.
- The fund has an expense ratio 0.7.
Returns
WhiteOak Capital Pharma and Healthcare Fund Direct Growth has given a CAGR return of 36.85% since inception.
Holdings
WhiteOak Capital Pharma and Healthcare Fund Direct Growth has allocated its funds majorly in Cash Equivalent, Health, Basic Materials, Financial Services. Its top holdings are Sun Pharmaceuticals Industries Ltd, Max Healthcare Institute Ltd Ordinary Shares, Cipla Ltd, Krishna Institute of Medical Sciences Ltd, Lupin Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 15%For long term (more than 1 year) capital gains will be taxed at 10% without indexation benefitDividends will always be taxed at slab rate. Gains upto Rs 1 lakh are exempt in case of long term.
Investment objective of WhiteOak Capital Pharma and Healthcare Fund Direct Growth
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. However, there can be no assurance that the investment objective of the Scheme will be realized.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 500.00 and for SIP is INR 100.00. WhiteOak Capital Pharma and Healthcare Fund Direct Growth has no lock in period.
Historical NAV & Returns
Annualised
▲
▼
488 people have invested ₹ 20.6L in WhiteOak Capital Pharma and Healthcare Fund Direct Growth in the last three months
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Overview
| Expense ratio | 0.69% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹254 Cr |
| Inception Date | 6 February, 2024 |
| Min Lumpsum/SIP | ₹500/₹100 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 73.27% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (20-Dec-24)
Fund Distribution
as on (30-Nov-24)
Small cap
33.4%
Large cap
26.1%
Mid cap
25%
Sector Allocation
Health
95%
Basic Materials
3.6%
Financial Services
1.4%
All changes are between Sep'24 and Nov'24
- This fund’s returns stands at 0.81% whereas the fund’s underlying benchmark Nifty 500 returns stands at -0.60% as on Nov'24
- This fund outperformed Nifty 500 by 1.40% in Nov'24
- AUM of the fund stands at 232 Cr as of Nov'24
- AUM increased by 31.9 Cr between Nov'24 and Oct'24
Top Stocks bought last month
Laurus Labs Ltd's allocation increased from 0.79% to 2.35%
Fortis Healthcare Ltd's allocation increased from 1.84% to 3.19%
Max Healthcare Institute Ltd Ordinary Shares's allocation increased from 5.11% to 6.26%
Top Stocks sold last month
Sun Pharmaceuticals Industries Ltd's allocation decreased from 9.58 % to 9.5 %
Cipla Ltd's allocation decreased from 5.53 % to 5.13 %
Poly Medicure Ltd's allocation decreased from 3.59 % to 2.85 %
Mid Cap allocation has gone up from 24.5% to 25%
Large Cap allocation has gone down from 27.1% to 26.1%
Small Cap allocation has gone up from 31.5% to 33.4%
Cash allocation has gone down from 14.8% to 13.3%
Top 3 Sectors in November were Health, Basic Materials & Financial Services
Nov'24
Health
95%
Basic Materials
4%
Financial Services
1%
Oct'24
Health
96%
Basic Materials
3%
Financial Services
1%
See all
Top Growth Drivers | 1M Return |
|---|---|
 Vimta Labs Ltd | 33.6% |
 Shaily Engineering Plastics Ltd | 32.5% |
 Vijaya Diagnostic Centre Ltd | 0.2% |
Loading...
We are taking more time than usual
Piyush Baranwal
Fund Manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth, since 6 February 2024
Top funds managed
Fund House
WhiteOak Capital Asset Management Limited
Total Schemes
Total AUM
₹14.87K Cr
as on 29-Nov-2024
Address
602B, 6th Floor,Indiabulls Finance Centre(IFC),1&2 Senapati Bapat Marg, Elphinstone Road (West) Mumbai Mumbai City
Phone
+91180030003060
Website
http://mf.whiteoakamc.com
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered returns of 36.85% since inception (6th February 2024)
Fund Allocations
This fund has an allocation of 86.69% in Equity, 0% in Debt and 13.31% in Cash related instruments
AUM size ₹254 Cr
This fund has AUM of ₹254 Cr which is less than its category average of ₹ 1857 Cr
Expense Ratio 0.69%
This fund has an expense ratio of 0.69% which is less than its category average expense ratio of 1.22%
Frequently Asked Questions for WhiteOak Capital Pharma and Healthcare Fund Direct Growth
The current NAV of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is ₹13.57 as on 20-Dec-2024.
Existing (Absolute + CAGR) as on 20-Dec-2024.
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | 5.95% | 5.95% |
6 Month Returns | 28.74% | 28.74% |
1 Year Returns | 0% | 0% |
3 Years Returns | 0% | 0% |
5 Years Returns | 0% | 0% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.69% as on November 2024
₹254 Cr as on November 2024
Sun Pharmaceuticals Industries Ltd(9.5%), Max Healthcare Institute Ltd Ordinary Shares(6.26%), Cipla Ltd(5.13%), Krishna Institute of Medical Sciences Ltd(3.37%), Lupin Ltd(3.35%) as on November 2024
Health(82.36%), Basic Materials(3.12%), Financial Services(1.21%) as on November 2024
The alpha ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | - | - | - |
As on November 2024
The alpha for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | - | - | - |
As on November 2024
The Beta for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | - | - | - |
As on November 2024
The sharpe ratio for WhiteOak Capital Pharma and Healthcare Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the WhiteOak Capital Pharma and Healthcare Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
WhiteOak Capital Pharma and Healthcare Fund Direct Growth | - | - | - |
As on November 2024
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Piyush Baranwal is the fund manager of WhiteOak Capital Pharma and Healthcare Fund Direct Growth
The Exit load of WhiteOak Capital Pharma and Healthcare Fund Direct Growth is 1%